anti-PTGFRN ADC

Anti-PTGFRN ADC refers to preclinical **antibody-drug conjugates targeting prostaglandin F2 receptor negative regulator** on tumor cells, developed primarily in oncology research by A&G Pharmaceutical and collaborators. Published work describes at least two distinct PTGFRN-directed ADC constructs rather than a single uniquely defined drug: a mouse monoclonal antibody **33B7** conjugated to **saporin**, and a fully human monoclonal antibody **8C7** conjugated to **duocarmycin**. These agents are designed to bind cell-surface PTGFRN, undergo internalization, and deliver a cytotoxic payload selectively to PTGFRN-expressing cancer cells. Reported preclinical activity has been shown in models including head and neck cancer, medulloblastoma, mesothelioma, and other PTGFRN-positive solid tumors, but the queried name itself is non-specific because it does not identify which anti-PTGFRN antibody, linker, or payload is intended.

Other names

anti-PTGFRN antibody-drug conjugateanti-PTGFRN ADC